Belimumab Completed Phase 4 Trials for Systemic Lupus Erythematosus Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01705977Belimumab Assessment of Safety in SLE
NCT04956484Belimumab In Early Systemic Lupus Erythematosus
NCT01632241Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
NCT01597492A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)